Filing Body
Page 1: UNITED STATES
Page 2: N/A
Page 3: PART I
Page 4: N/A
Page 5: N/A
Page 6: N/A
Page 7: N/A
Page 8: N/A
Page 9: Emerging Markets
Page 10: N/A
Page 11: Strategic Alliances and Collaborations
Page 12: Current Marketed Products In-Licensed
Page 13: Otsuka
Page 14: Current Marketed Products Internally Discovered
Page 15: Otsuka
Page 16: Abbott
Page 17: United States
Page 18: Biologic products
Page 19: Japan
Page 20: Competition
Page 21: Government Regulation and Price Constraints
Page 22: N/A
Page 23: Sources and Availability of Raw Materials
Page 24: Environmental Regulation
Page 25: Bristol-Myers Squibb Website
Page 26: We face intense competition from other pharmaceutical manufacturers, including for both innovative m
Page 27: Part D Formularies and product pricing in general, (iv) delays in gaining reimbursement and/or reduc
Page 28: We may experience difficulties or delays in the development and commercialization of new products.
Page 29: position. There are risks associated with this strategy. We may not be able to consistently replenis
Page 30: N/A
Page 31: PART IA
Page 32: N/A
Page 33: PART II
Page 34: Issuer Purchases of Equity Securities
Page 35: Five Year Financial Summary
Page 36: EXECUTIVE SUMMARY
Page 37: N/A
Page 38: Strategy
Page 39: Product and Pipeline Developments
Page 40: N/A
Page 41: N/A
Page 42: RESULTS OF OPERATIONS
Page 43: N/A
Page 44: N/A
Page 45: Key Products
Page 46: N/A
Page 47: N/A
Page 48: Estimated End-User Demand
Page 49: Expenses
Page 50: Marketing, selling and administrative
Page 51: Other (income)/expense
Page 52: Income Taxes
Page 53: Discontinued Operations
Page 54: Credit Ratings
Page 55: Investing Activities
Page 56: SEC Consent Order
Page 57: Revenue Recognition
Page 58: Pharmaceutical Company Fee (Pharma Fee)
Page 59: Business Combinations
Page 60: Indefinite-Lived Intangible Assets, including IPRD
Page 61: Special Note Regarding Forward-Looking Statements
Page 62: Foreign Exchange Risk
Page 63: BRISTOL-MYERS SQUIBB COMPANY
Page 64: BRISTOL-MYERS SQUIBB COMPANY
Page 65: BRISTOL-MYERS SQUIBB COMPANY
Page 66: BRISTOL-MYERS SQUIBB COMPANY
Page 67: Note 1. ACCOUNTING POLICIES
Page 68: Marketable Securities and Investments in Other Companies
Page 69: Restructuring
Page 70: Recently Issued Accounting Standards
Page 71: Note 3. ALLIANCES AND COLLABORATIONS
Page 72: N/A
Page 73: Otsuka
Page 74: Lilly
Page 75: Gilead
Page 76: Pfizer
Page 77: ZymoGenetics, Inc. Acquisition
Page 78: Note 5. MEAD JOHNSON NUTRITION COMPANY INITIAL PUBLIC OFFERING AND SPLIT-OFF
Page 79: Note 6. RESTRUCTURING
Page 80: Effective Tax Rate
Page 81: Deferred Taxes and Valuation Allowance
Page 82: N/A
Page 83: Note 9. EARNINGS PER SHARE
Page 84: Note 10. FINANCIAL INSTRUMENTS
Page 85: Available-For-Sale Securities and Cash Equivalents
Page 86: Qualifying Hedges and Non-Qualifying Derivatives
Page 87: Short-Term Borrowings and Long-Term Debt
Page 88: Note 11. RECEIVABLES
Page 89: Note 13. PROPERTY, PLANT AND EQUIPMENT
Page 90: Note 15. ACCRUED EXPENSES
Page 91: Note 18. EQUITY
Page 92: Note 19. PENSION, POSTRETIREMENT AND POSTEMPLOYMENT LIABILITIES
Page 93: N/A
Page 94: Actuarial Assumptions
Page 95: Plan Assets
Page 96: Contributions
Page 97: Termination Indemnity Plans
Page 98: N/A
Page 99: Fair Value Assumptions
Page 100: Note 22. LEGAL PROCEEDINGS AND CONTINGENCIES
Page 101: inter partes
Page 102: OTHER INTELLECTUAL PROPERTY LITIGATION
Page 103: GENERAL COMMERCIAL LITIGATION
Page 104: Reglan
Page 105: OTHER PROCEEDINGS
Page 106: Note 24. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
Page 107: N/A
Page 108: Internal Control Integrated Framework
Page 109: Evaluation of Disclosure Controls and Procedures
Page 110: Internal Control Integrated Framework
Page 111: PART III
Page 112: PART IV
Page 113: N/A
Page 114: EXHIBIT INDEX
Page 115: N/A
Page 116: N/A
Page 117: N/A
Exhibits
EX-10.(Z)
EX-10.(BB)
EX-10.(CC)
EX-10.(DD)
EX-10.(LL)
EX-12
EX-21
EX-23
EX-31.(A)
EX-31.(B)
EX-32.(A)
EX-32.(B)
EX-101.INS
EX-101.SCH
EX-101.CAL
EX-101.DEF
EX-101.LAB
EX-101.PRE
Interactive Data
XBRL Viewer